ACADIA Pharmaceuticals (NASDAQ:ACAD) Earns Outperform Rating from Analysts at Wolfe Research

Wolfe Research started coverage on shares of ACADIA Pharmaceuticals (NASDAQ:ACAD) in a research note released on Monday morning, Marketbeat Ratings reports. The firm issued an outperform rating and a $33.00 target price on the biopharmaceutical company’s stock.

A number of other analysts have also recently commented on the company. HC Wainwright reissued a “buy” rating and issued a $37.00 target price on shares of ACADIA Pharmaceuticals in a report on Tuesday, February 3rd. Piper Sandler set a $37.00 target price on shares of ACADIA Pharmaceuticals in a report on Tuesday, December 16th. UBS Group lifted their price target on shares of ACADIA Pharmaceuticals from $35.00 to $40.00 and gave the stock a “buy” rating in a research note on Tuesday, January 6th. Citigroup boosted their price target on ACADIA Pharmaceuticals from $33.00 to $36.00 and gave the company a “buy” rating in a report on Tuesday, January 6th. Finally, Wall Street Zen downgraded ACADIA Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, January 31st. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $31.35.

ACADIA Pharmaceuticals Trading Up 1.9%

ACAD stock opened at $25.05 on Monday. ACADIA Pharmaceuticals has a 12-month low of $13.40 and a 12-month high of $28.35. The stock has a market capitalization of $4.24 billion, a PE ratio of 16.16, a price-to-earnings-growth ratio of 8.63 and a beta of 0.66. The stock’s 50 day simple moving average is $25.62 and its 200 day simple moving average is $24.45.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last released its quarterly earnings data on Wednesday, February 25th. The biopharmaceutical company reported $1.60 EPS for the quarter, topping the consensus estimate of $0.12 by $1.48. The company had revenue of $298.00 million during the quarter, compared to the consensus estimate of $292.54 million. ACADIA Pharmaceuticals had a return on equity of 14.61% and a net margin of 24.94%.ACADIA Pharmaceuticals’s revenue for the quarter was up 9.4% on a year-over-year basis. During the same period last year, the company earned $0.86 EPS. On average, research analysts predict that ACADIA Pharmaceuticals will post 0.7 earnings per share for the current year.

Insider Activity

In other ACADIA Pharmaceuticals news, EVP Jennifer J. Rhodes sold 6,950 shares of the firm’s stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $23.38, for a total transaction of $162,491.00. Following the completion of the transaction, the executive vice president owned 7,609 shares in the company, valued at $177,898.42. This trade represents a 47.74% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Company insiders own 26.50% of the company’s stock.

Hedge Funds Weigh In On ACADIA Pharmaceuticals

Institutional investors have recently bought and sold shares of the business. Farther Finance Advisors LLC increased its holdings in shares of ACADIA Pharmaceuticals by 67.5% in the 4th quarter. Farther Finance Advisors LLC now owns 958 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 386 shares during the last quarter. Meeder Asset Management Inc. purchased a new position in ACADIA Pharmaceuticals in the fourth quarter worth about $26,000. Geneos Wealth Management Inc. increased its stake in ACADIA Pharmaceuticals by 113.0% during the third quarter. Geneos Wealth Management Inc. now owns 1,425 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 756 shares during the last quarter. Smartleaf Asset Management LLC increased its position in shares of ACADIA Pharmaceuticals by 107.0% during the 3rd quarter. Smartleaf Asset Management LLC now owns 1,712 shares of the biopharmaceutical company’s stock valued at $36,000 after purchasing an additional 885 shares during the last quarter. Finally, Transamerica Financial Advisors LLC raised its holdings in ACADIA Pharmaceuticals by 304.5% during the 4th quarter. Transamerica Financial Advisors LLC now owns 1,335 shares of the biopharmaceutical company’s stock valued at $36,000 after buying an additional 1,005 shares during the period. Institutional investors own 96.71% of the company’s stock.

ACADIA Pharmaceuticals News Summary

Here are the key news stories impacting ACADIA Pharmaceuticals this week:

• Positive Sentiment: Quarterly earnings sharply beat estimates — ACAD reported $1.60 EPS vs. $0.13 consensus and revenue of $298M vs. $292.5M, showing healthy margins and ROE that support near‑term cash generation. Earnings and Call
• Positive Sentiment: FY‑2026 revenue guidance was updated to roughly $1.2B–$1.3B, in line with consensus (~$1.2B), which supports continued topline growth expectations and reduces near‑term model uncertainty. (Note: the company did not publish a clear EPS range in the release.) Press Release
• Positive Sentiment: Wolfe Research initiated coverage with an “outperform” and a $33 price target (~32% upside), which can attract attention from growth/value managers and help support the rally. Wolfe Research Initiation
• Neutral Sentiment: Management hosted a conference call and published a slide deck with additional color on product mix and pipeline priorities — useful for investors who want to dig into assumptions behind guidance. Slide Deck
• Neutral Sentiment: Reported short‑interest data shows zero shares and NaN changes, indicating a data/reporting error — this figure is unreliable and should not be taken as evidence of buildup or covering. (No actionable short‑interest signal.)
• Neutral Sentiment: ACADIA will participate in upcoming investor conferences, which may sustain investor interest but are unlikely to move the stock materially unless new data or announcements are revealed. Investor Conferences

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company’s flagship product, NUPLAZID® (pimavanserin), received U.S.